骨髓性白血病

Results In those patients with marrow invasion , 4 cases in I phase（4.2%）,12 cases in II phase（12.6%）,36 cases in Ⅲ phase（37.9%）and 43 cases in Ⅳ phase(47.4%);small lymphocytic、diffuse cleaved cell、lymphoblastic lymphoma are main pathologic types;patients with mediastinal lymphadenectasis、splenomegaly and spleen violations are prone to catch bone marrow involvement;56 cases of anemia in patients with bone marrow involuement(58.9%), 42 patients with thrombocytopenia (44.2%),27 cases with leukopenia (28.4%),49 cases of patients leukocyte increased (51.6%),so,anemia is common;three were 30 cases with three items abnormal（31.6％）and 65 cases with one item abnormal at least (68.4%),the incidence of abnormal peripheral blood in leukocythemia patients were higher than that in patients with bone marrow infiltration,Particularly the patients with increased leukocyte or three items abnormalities were more common in leukemia; Abnormal cells in peripheral blood were observed in 66 cases (69.5%); chemotherapy efficiency reached 65.2% in the patients with bone marrow involuement,the median survival time was 11.5 months.

结果发生骨髓侵犯病例中I期4例（4.2%）， II期12例（12.6%），Ⅲ期36例（37.9%），Ⅳ期43例(47.4%)；病理类型以小淋巴细胞性，弥漫型裂细胞性（改为：弥漫性大B细胞型淋巴瘤）和淋巴母细胞性淋巴瘤多见；纵隔淋巴结肿大、脾脏肿大和脾受侵患者易发生骨髓侵犯；骨髓侵犯患者外周血中贫血56例(58.9%)，血小板减少42例(44.2%)，白细胞减少27例(28.4%)，白细胞增高49例(51.6%)，以贫血多见；三项均异常30例(31.6%)，至少一项不正常65例(68.4%)，淋巴瘤细胞白血病患者外周血象异常发生率高于骨髓浸润患者，尤其是白细胞增高或三项均异常者更常见于白血病；66例(69.5%)外周血分类中发现异常细胞；骨髓侵犯化疗有效率65.2%，中位生存期11.5个月。

Results In those patients with marrow invasion , 4 cases in I phase（4.2%）,12 cases in II phase（12.6%）,36 cases in Ⅲ phase（37.9%）and 43 cases in Ⅳ phase(47.4%);small lymphocytic、diffuse cleaved cell、lymphoblastic lymphoma are main pathologic types;patients with mediastinal lymphadenectasis、splenomegaly and spleen violations are prone to catch bone marrow involvement;56 cases of anemia in patients with bone marrow involuement(58.9%)恶性淋巴瘤症状, 42 patients with thrombocytopenia (44.2%),27 cases with leukopenia (28.4%),49 cases of patients leukocyte increased (51.6%),so,anemia is common;three were 30 cases with three items abnormal（31.6％）and 65 cases with one item abnormal at least (68.4%),the incidence of abnormal peripheral blood in leukocythemia patients were higher than that in patients with bone marrow infiltration,Particularly the patients with increased leukocyte or three items abnormalities were more common in leukemia; Abnormal cells in peripheral blood were observed in 66 cases (69.5%); chemotherapy efficiency reached 65.2% in the patients with bone marrow involuement,the median survival time was 11.5 months.

结果发生骨髓侵犯病例中I期4例（4.2%）， II期12例（12.6%），Ⅲ期36例（37.9%）恶性淋巴瘤分期，Ⅳ期43例(47.4%)；病理类型以小淋巴细胞性，弥漫型裂细胞性（改为：弥漫性大B细胞型淋巴瘤）和淋巴母细胞性淋巴瘤多见；纵隔淋巴结肿大、脾脏肿大和脾受侵患者易发生骨髓侵犯；骨髓侵犯患者外周血中贫血56例(58.9%)，血小板减少42例(44.2%)，白细胞减少27例(28.4%)，白细胞增高49例(51.6%)，以贫血多见；三项均异常30例(31.6%)，至少一项不正常65例(68.4%)，淋巴瘤细胞白血病患者外周血象异常发生率高于骨髓浸润患者，尤其是白细胞增高或三项均异常者更常见于白血病；66例(69.5%)外周血分类中发现异常细胞；骨髓侵犯化疗有效率65.2%，中位生存期11.5个月。

Therefore it is tried for the treatment of CML which is a disease with highly increased marrow cellularity .

因此用它来治疗慢性粒细胞性白血病，一种骨髓细胞过度增生性疾病。

Methods Clinical observations were made in 36 patients with acute myelogenous leukemia receiving intensive chemotherapy of HDAraC （10～18g） when they obtained complete remission after induction therapy.

观察大剂量阿糖胞苷总量（10～18g）强化治疗36例诱导缓解后的急性髓性白血病的毒副反应：骨髓抑制、眼毒性、黏膜溃疡、肺损、肝损、肾损、消化道损害等。8%的患者出现肝损害，2.78%的患者出现心脏毒性，11。。。。

Methods Clinical observations were made in 36 patients with acute myelogenous leukemia receiving intensive chemotherapy of HDAraC （10～18g） when they obtained complete remission after induction therapy. Results Reactions of digestive tract such as nausea and vomiting occurred in 69.4% of the patients.

观察大剂量阿糖胞苷总量（10～18g）强化治疗36例诱导缓解后的急性髓性白血病的毒副反应：骨髓抑制、眼毒性、黏膜溃疡、肺损、肝损、肾损、消化道损害等。

Such massive splenomegaly is usually indicative of some myeloproliferative disease such as chronic myelogenous leukemia or myelofibrosis.

这样的脾肿大通常预示有骨髓增生型疾病，例如慢性髓性白血病或骨髓纤维化。

Such massive splenomegaly is usually indicative of some myeloproliferative disease such as chronic myelogenous leukemia or myelofibrosis .

这样的脾肿大通常预示有骨髓增生型疾病，例如慢性髓性白血病或骨髓纤维化。你知道它的英文吗？

Chronic lymphocytic leukemia is a blood and bone marrow cancer that affects 10,000 new patients each year in the United States.

慢性淋巴细胞性白血病是一种血液和骨髓肿瘤，在美国每年有10，000新患者。

Methods: Nonadherent cells from bone marrow or peripheral blood mononuclear cells of 8 patients with chronic myeloid leukemia were cultured with rhGM- CSF and rhIL- 4. The cytokines were supplemented every three days. RhTNF-α was used at the ninth day. All the cells were harvested at the twelfth day.

从8例慢性髓性白血病患者的骨髓或外周血中获取非贴壁细胞，利用细胞因子(rhGM蛳CSF、rhIL蛳4、rhTNF蛳α)联合培养，每3 d补充新的细胞因子，其中rhTNF蛳α为第9天添加，第12天收获细胞。

Thirty patients with acute promyelocytic leukemia were observed between September 1977 and October 1985. Bleeding diathesis with petechiae or ecchymosis (80%) was the most common presenting symptom. Seventeen of 24 patients with pretreated coagulation studies were diagnosed to have disseminated intravascular coagulation. Six out of 11 patients died from intracranial hemorrhage after a mean of 2.5 days of hospitalization without any treatment. DIC was responsible for death in most cases. Induction therapy with anthracycline and cytosine arabinoside combined with prophylactic heparin infusion was carried out in the remaining 19 patients. Two patients were incompletely treated. Eight out of 17 patients achieved complete remission after a mean of 63 days following chemotherapy. The remission rate was 47%.

自1977年9月至1985年10月，观察30位急性前骨髓球性白血病病帣，临床上诊断时初发症状，主要为出血现象，尤其以瘀斑出血最多，占80%。24位病人作治疗前凝血机能检查，17位出现播散性血管内凝固症候群。11位病人没有接受治疗，其中6位经诊断后平均2.5天内死於脑内出血，凝血机能检验显示5位有播散性血管内凝固症候群。19位病人接受anthracycline与ara-C并用预防性肝素静脉滴注作缓解诱导治疗，2位不完全治疗，其余17位中有8位经过平均63天之化学治疗得到完全缓解，缓解率47%。

This one mode pays close attention to network credence foundation of the businessman very much.

这一模式非常关注商人的网络信用基础。

Cell morphology of bacterial ghost of Pasteurella multocida was observed by scanning electron microscopy and inactivation ratio was estimated by CFU analysi.

扫描电镜观察多杀性巴氏杆菌细菌幽灵和菌落形成单位评价遗传灭活率。